This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Buy Nektar (NKTR) Ahead of Earnings?
by Zacks Equity Research
Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
The focus will be on Nektar Therapeutics' (NKTR) pipeline progress and launch plans for NKTR-181 when the company reports second-quarter results.
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q2 Earnings?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) second-quarter conference call, investor focus will be on the initial sales uptick of its newly launched anti-epileptic drug Epidiolex.
CannTrust (CTST) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
On CannTrust's (CTST) second-quarter earnings call, investor focus will be on the company's efforts to resolve matters regarding the non-compliant report issued by Health Canada.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Nektar (NKTR) Down 7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cancer-Fighting Stocks & ETF: What You Need to Know
by Neena Mishra
Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference
Nektar (NKTR) in Focus: Stock Moves 8.8% Higher
by Zacks Equity Research
Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Why Cancer-Fighting Stocks & ETFs Are Soaring
by Neena Mishra
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary
by Zacks Equity Research
Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.
3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates
by Zacks Equity Research
So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.
Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 4.23% and 10.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
The focus will be on Nektar Therapeutics' (NKTR) pipeline progress when the company reports first-quarter results.
Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar (NKTR) Down 17.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stock Market News For Mar 7, 2019
by Zacks Equity Research
Benchmarks ended in the red on Wednesday after a slew of weak economic reports weighed on the markets.
Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. The FDA extends the review period for NKTR-181 NDA by three months.
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
Nektar Therapeutics (NKTR) will report fourth-quarter results on Feb 28. Investors are expected to focus on pipeline progress.
Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration
by Zacks Equity Research
Nektar (NKTR) and ImaginAb enter into a license and clinical trial collaboration, allowing Nektar to use ImaginAb's immuno-oncology imaging technology.
BioXcel Surges on Fast Track Designation to Agitation Drug
by Zacks Equity Research
BioXcel (BTAI) soars after the FDA granted Fast Track designation to its lead candidate, BXCL501.
Nektar (NKTR) Up 7.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Catches Eye: Stock Jumps 8.7%
by Zacks Equity Research
Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.